Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview.
The Global Initiative for Asthma Report updated in 2019 stated that potential benefits of allergen immunotherapy (AIT), compared to pharmacological and avoidance options, must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy in asthma. Thus, with the aim of clarifying some aspects with regard to the possible use of AIT in allergic asthma treatment armamentarium, a group of expert allergists from the Spanish Allergy and Clinical Immunology Scientific Society (SEAIC), particularly from the Immunotherapy and Asthma Interest Groups developed a frequently asked questions in clinical practice. This document updates relevant topics on the use of AIT in asthma and could facilitate physician clinical decisions and improve health outcomes for individual patients.
['Tabar|Ana I|AI|', 'Delgado|Julio|J|', 'González-Mancebo|Eloina|E|', 'Arroabarren|Esozia|E|', 'Soto Retes|Lorena|L|', 'Domínguez-Ortega|Javier|J|', '|||']
D000367:Age Factors D000485:Allergens D000918:Antibody Specificity D001249:Asthma D015415:Biomarkers D000066491:Clinical Decision-Making D002986:Clinical Trials as Topic D003362:Cost-Benefit Analysis D003888:Desensitization, Immunologic D019468:Disease Management D006801:Humans D007073:Immunoglobulin E D011379:Prognosis D012720:Severity of Illness Index D016896:Treatment Outcome
Immunotherapy Asthma Allergy Clinical practice